Hepatitis A immunity in Yozgat, Turkey
- PMID: 30712049
- PMCID: PMC6464676
- DOI: 10.5144/0256-4947.2019.37
Hepatitis A immunity in Yozgat, Turkey
Abstract
Background: Since routine immunization could change the epidemiological profile of hepatitis A virus (HAV) infection in the future, it is important to determine the baseline immunity to HAV across Turkey.
Objective: The aim of this study was to determine the seroprevalence of hepatitis A among individuals 6 years of age and older in Yozgat, Turkey.
Design: Cross-sectional.
Setting: Community in central region of Turkey.
Patients and methods: Questionnaires and blood specimens were collected and the presence of hepatitis A IgG antibodies against hepatitis A virus was determined quantitatively by ELISA.
Main outcome measures: The rates of hepatitis A immunity by age group.
Sample size: 1862.
Results: Immunity to hepatitis A was 79.1% (n=1473). The mean (SD) age was 17.1 (14.7) years in the nonimmune group and 37.8 (19.5) years in the immune group (P less than .001), and immunity increased with age. No significant difference in immunity rate was detected between gen.ders in children and adults. The seropositivity rate for subjects ages 6-19 years was lower than in subjects aged 20-96 years (52.2% versus 93.9%; P less than .001).
Conclusion: A catch-up vaccination program is needed for persons aged 6-19 years in Yozgat.
Limitations: Single region data which can not be generalized. For this reason, a multi-centered study that can reflect the whole country is recommended.
Conflict of interest: None.
Conflict of interest statement
Figures
References
-
- Melhem NM, Jaffa M, Zaatari M, Awada H, Salibi NE, Ramia S. The changing pattern of hepatitis A in Lebanese adults. Int J Infect Dis. 2015 Jan;30:87–90. - PubMed
-
- Lai M, Chopra S. Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis. [accessed 2018, 31 July]. Available from: https://www.uptodate.com/contents/hepatitis-a-virus-infection-in-adults-....
-
- World Health Organization. WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec. 2012;87:261–76. - PubMed
-
- Merat S, Rezvan H, Nouraie M, Abolghasemi H, Jamali R, Amini-Kafiabad S, et al. Seroprevalence and risk factors of hepatitis A virus infection in Iran: a population based study. Arch Iran Med. 2010 Mar;13(2):99–104. - PubMed
-
- Prevention of Hepatitis A Through Active or Passive Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [accessed 2018 31 July];MMWR Recommendations and Reports. 2006 55:1–23. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm. - PubMed
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials